Form 8-K - Current report:
SEC Accession No. 0001104659-24-121612
Filing Date
2024-11-21
Accepted
2024-11-21 17:15:17
Documents
13
Period of Report
2024-11-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2429156d1_8k.htm   iXBRL 8-K 29507
  Complete submission text file 0001104659-24-121612.txt   203682

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA iova-20241115.xsd EX-101.SCH 3003
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE iova-20241115_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE iova-20241115_pre.xml EX-101.PRE 22351
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2429156d1_8k_htm.xml XML 3702
Mailing Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070 6502607120
IOVANCE BIOTHERAPEUTICS, INC. (Filer) CIK: 0001425205 (see all company filings)

EIN.: 753254381 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36860 | Film No.: 241485503
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)